Document Detail

Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.
MedLine Citation:
PMID:  3012486     Owner:  NLM     Status:  MEDLINE    
Acebutolol is a new hydrophilic, cardioselective beta-adrenergic-blocking agent that possesses partial agonist and membrane-stabilizing activities. In the treatment of mild to moderate essential hypertension, once-daily acebutolol as monotherapy provides effective control in a large majority of patients and produces a further reduction in blood pressure when used concomitantly with diuretics. Acebutolol is as effective as other beta-blocking agents, and in a large, double-blind, parallel study against propranolol was found to cause less reduction in heart rate, and fewer neurologic side effects and patient withdrawals due to adverse effects. Oral acebutolol is also effective in suppressing premature ventricular contractions, and in small numbers of patients generally beneficial results were obtained in supraventricular and ventricular arrhythmias with intravenous administration. These salutary effects are attributable to beta blockade. Controlled clinical trials documented the antianginal actions of oral acebutolol in chronic stable angina pectoris; its efficacy in this regard is comparable to that of other beta-blocking agents. The drug produces smaller decreases in heart rate and cardiac output and alterations in peripheral vascular hemodynamics than beta-blocking drugs without partial agonist activity, and because of its cardioselectivity, it may be used cautiously in patients with bronchospastic disease. Acebutolol has minimal metabolic effects and does not elevate levels of blood lipids during long-term therapy; high-density-lipoprotein cholesterol increased with acebutolol in a small number of patients.
B N Singh; W R Thoden; J Wahl
Related Documents :
12912816 - Comparative effects of carvedilol and metoprolol on regional vascular responses to adre...
24269136 - Clinical parameters associated with pressure ulcer healing in patients with advanced il...
22743796 - 'long' pressure reactivity index (l-prx) as a measure of autoregulation correlates with...
10652966 - Mechanisms of development of heart failure in the hypertensive patient.
2137636 - Potential of radio-frequency balloon angioplasty: weld strengths, dose-response relatio...
23973686 - Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  6     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:    1986 Mar-Apr
Date Detail:
Created Date:  1986-07-14     Completed Date:  1986-07-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  45-63     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acebutolol* / administration & dosage,  adverse effects,  analogs & derivatives,  metabolism,  pharmacology,  therapeutic use
Angina Pectoris / drug therapy
Arrhythmias, Cardiac / drug therapy
Central Nervous System / drug effects,  metabolism
Drug Administration Schedule
Drug Interactions
Heart / drug effects*
Heart Conduction System / drug effects
Hemodynamics / drug effects
Hypertension / drug therapy
Myocardial Contraction / drug effects
Receptors, Adrenergic, beta / drug effects
Respiration / drug effects
Reg. No./Substance:
0/Receptors, Adrenergic, beta; 28197-69-5/diacetolol; 37517-30-9/Acebutolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of fat, fiber, nitrate, and food additives in carcinogenesis: a critical evaluation and recomme...
Next Document:  ACTH1-4 potentiates alpha-MSH-induced melanophore dispersion and excessive grooming.